Valuation: Fortress Biotech, Inc.

Market Cap 9.4Cr 8.12Cr 7.64Cr 6.95Cr 13Cr 901.13Cr 13Cr 90Cr 35Cr 450.69Cr 35Cr 35Cr 1.5TCr P/E 2026 *
1.18x
P/E 2027 * -5.64x
Enterprise Value 9.4Cr 8.12Cr 7.64Cr 6.95Cr 13Cr 901.13Cr 13Cr 90Cr 35Cr 450.69Cr 35Cr 35Cr 1.5TCr EV / Sales 2026 *
1.18x
EV / Sales 2027 * 0.76x
Free-Float
77.3%
Yield 2026 *
-
Yield 2027 * -
1 day-0.18%
1 week+7.47%
Current month-10.38%
1 month-15.77%
3 months+13.10%
6 months-18.70%
Current year-23.36%
1 week 2.57
Extreme 2.57
3.06
1 month 2.57
Extreme 2.57
3.65
Current year 2.18
Extreme 2.18
4.53
1 year 1.99
Extreme 1.9907
4.53
3 years 1.24
Extreme 1.24
7.2
5 years 1.24
Extreme 1.24
57.15
10 years 1.24
Extreme 1.24
91.5
Manager TitleAgeSince
Chief Executive Officer 71 20/12/2013
Director of Finance/CFO 51 22/02/2012
Director of Finance/CFO 36 16/08/2022
Director TitleAgeSince
Director/Board Member 74 01/12/2008
Chairman 71 20/12/2013
Director/Board Member 63 01/06/2006
Date Insider Type Main position Quantity % Market Cap.
01/01/26 Free

Director

27,322 0.0880%
01/01/26 Free

Director

27,322 0.0880%
01/01/26 Free

Director

27,322 0.0880%
Change 5-day change 1-year change 3-year change Capi.($)
-0.18%+7.47%+24.67%-57.04% 9.4Cr
+1.64%+2.53%+42.38%+0.58% 8.05TCr
-1.10%-2.42%-3.61%+28.98% 5.06TCr
+0.88%-3.93%+11.18%+169.94% 4.76TCr
+17.25%+17.36%-41.63%-41.46% 4.58TCr
+1.87%+4.52%+56.79%-18.40% 3.09TCr
-1.51%+5.28%+127.02%-37.25% 2.57TCr
+0.09%+2.10%+45.56%+93.02% 2.5TCr
+1.36%-0.67%-0.87%+195.57% 2.12TCr
+1.49%+5.26%+65.34%+127.30% 1.67TCr
Average +2.19%+0.32%+32.68%+46.12% 3.44TCr
Weighted average by Cap. +2.87%-0.61%+26.42%+42.90%

Financials

2026 *2027 *
Net sales 7.99Cr 6.9Cr 6.49Cr 5.9Cr 11Cr 765.32Cr 11Cr 76Cr 30Cr 382.77Cr 30Cr 29Cr 1.27TCr 12Cr 11Cr 10Cr 9.08Cr 17Cr 1.18TCr 17Cr 117.25Cr 46Cr 589.42Cr 46Cr 45Cr 1.96TCr
Net income 9.05Cr 7.82Cr 7.36Cr 6.68Cr 13Cr 867.23Cr 13Cr 86Cr 34Cr 433.74Cr 34Cr 33Cr 1.44TCr -2.08Cr -1.8Cr -1.69Cr -1.54Cr -2.89Cr -199.66Cr -2.94Cr -20Cr -7.78Cr -100Cr -7.82Cr -7.65Cr -332.61Cr
Net Debt - -
Logo Fortress Biotech, Inc.
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.
Employees
78
Date Price Change Volume
18/26/18 $2.805 -0.53% 3,04,671
17/26/17 $2.820 -3.75% 8,38,776
14/26/14 $2.930 -1.68% 10,31,522
13/26/13 $2.980 +8.36% 13,94,128
12/26/12 $2.750 +5.36% 10,07,762
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.820USD
Average target price
11.00USD
Spread / Average Target
+290.07%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. FBIO Stock